Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
Kume
Osamu
O
Department of Internal Medicine 1, Oita University, Oita, Japan.
Takahashi
Naohiko
N
Wakisaka
Osamu
O
Nagano-Torigoe
Yasuko
Y
Teshima
Yasushi
Y
Nakagawa
Mikiko
M
Yufu
Kunio
K
Hara
Masahide
M
Saikawa
Tetsunori
T
Yoshimatsu
Hironobu
H
D000284:Administration, Oral; D000818:Animals; D001281:Atrial Fibrillation / Q000503:physiopathology / Q000517:prevention & control*; D015153:Blotting, Western; D004195:Disease Models, Animal; D004452:Echocardiography; D005355:Fibrosis / Q000188:drug therapy* / Q000473:pathology; D006325:Heart Atria / Q000187:drug effects* / Q000473:pathology*; D007249:Inflammation / Q000473:pathology / Q000517:prevention & control; D018836:Inflammation Mediators / Q000032:analysis; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000032:analysis; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000473:pathology; D000077205:Pioglitazone; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D045162:Thiazolidinediones / Q000494:pharmacology*
D018836:Inflammation Mediators; D045162:Thiazolidinediones; D020780:Matrix Metalloproteinase 9; D000077205:Pioglitazone